Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | L1₹118Accepted-AOC | L1 | Accepted-AOC Bidder Not Matched to L1 Rates | |
| 2 | L1₹1.9 LAccepted-AOC C 21 22 23 SECTOR 3 NOIDA GB NAGAR UP UNICURE INDIA LTD NOIDA SECTOR 3 GAUTAM BUDH NAGAR GAUTAM BUDDHA NAGAR UTTAR PRADESH 201301 | GAUTAM BUDDHA NAGAR | UTTAR PRADESH | 201301 | L1 | Accepted-AOC L1 Bidder | |
| 3 | L1₹6.3 LAccepted-AOC | L1 | Accepted-AOC L1 Bidder | |
| 4 | L2₹88.74Accepted-AOC | L2 | Accepted-AOC Bidder Not Matched to L1 Rates | |
| 5 | L3₹149Accepted-AOC | L3 | Accepted-AOC Bidder Not Matched to L1 Rates |
| Sl No | Description | Qty | Unit | HINDUSTAN LABORATORIES LIMITED | CONCORD DRUGS LIMITED | UNICURE INDIA LTD | Super Formulations Pvt Ltd | PURE AND CURE HEALTHCARE PRIVATE LIMITED | Shangrila Industries Pvt. Ltd. | PHARMAROOTS HEALTHCARE |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | Atorvastatin + Clopidogrel + Aspirin Capsules IP
Strength: Each Hard Gelatin Capsule Contains
Atorvastatin Calcium IP Equivalent to
Atorvastatin - 20mg (As Film Coated Tablet)
Clopidogrel Bisulphate IP Equivalent to Clopidogrel - 75mg
Aspirin IP - 75mg (As Gastro Resistant Tablet)
Packing: Blister with Aluminium Back | 1 | 10 X 10 Caps | - | 249 ₹278.88 | 162.13 ₹181.59 | - | 193.32 ₹216.52 | 182 ₹203.84 | 118 ₹132.16 Lowest |
| 2.00 | Aspirin + Clopidogrel (150mg + 150mg) Capsules IP
Strength: Each Hard Gelatin Capsule Contains
Aspirin IP - 150mg (as Enteric Coated Pellet Form)
Clopidogrel Bisulphate IP Equivalent to Clopidogrel - 150mg (as Pellet Form)
Packing: Blister with Aluminium Back | 1 | 10 X 10 Caps | - | 169 ₹189.28 Lowest | 203 ₹227.36 | - | - | - | - |
| 3.00 | Aspirin + Clopidogrel (75mg + 75mg) Capsules IP
Strength: Each Hard Gelatin Capsule Contains
Aspirin IP - 75mg (as Enteric Coated Pellet Form)
Clopidogrel Bisulphate IP Equivalent to Clopidogrel - 75mg (as Pellet Form)
Packing: Blister with Aluminium Back | 1 | 10 X 10 Caps | - | 99 ₹110.88 Lowest | 133 ₹148.96 | - | - | 165 ₹184.8 | - |
| 4.00 | Aspirin Tablets IP - 300mg
Strength: Each Gastro Resistant Tablet Contains
Aspirin IP - 300mg
Packing: Aluminium Foil Strip | 1 | 10 X 10 Tabs | - | - | 78.12 ₹87.49 Lowest | 88.74 ₹99.39 | - | - | - |
| 5.00 | Clopidogrel Tablets IP - 150mg
Strength: Each Film coated Tablet Contains
Clopidogrel Bisulphate IP Equivalent to Clopidogrel - 150mg
Packing: Blister with Aluminium Back | 1 | 10 X 10 Tabs | 155.16 ₹173.78 | 125 ₹140 Lowest | 138.11 ₹154.68 | - | - | 149 ₹166.88 | - |
| 6.00 | Clopidogrel Tablets IP - 300mg
Strength: Each Film coated Tablet Contains
Clopidogrel Bisulphate IP Equivalent to Clopidogrel - 300mg
Packing: Blister with Aluminium Back | 1 | 10 X 10 Tabs | 264.77 ₹296.54 | - | 262 ₹293.44 Lowest | - | - | - | - |
| 7.00 | Hydroxyurea Capsules IP - 500mg
Strength: Each Hard Gelatin Capsule Contains
Hydroxyurea IP - 500mg
Packing: Blister with Aluminium Back | 1 | 5 X 10 Caps | - | - | - | - | - | - | - |
Tender Value
Refer Docs
EMD Value
₹1.5 L
Closing Date
18 Jun 2025, 3:00 pmClosed
General Manager (Drugs)
TNMSC Limited, No. 417, Pantheon Road, Egmore, Chennai - 600008
Online Re-Tender for the supply of Essential Drugs and Medicines to TNMSC Limited under rate contract system for one year from the date of acceptances
2025_TNMSC_561713_1
e-011/M(P)/RE-DRUG-2/TNMSC/25
Open Tender
Medicines
Supply
60 days
TamilNadu
Please refer Tender documents.
24 documents required · 24 mandatory
₹0
₹1.5 L
Yes
30 Oct 2025
28 May 2025
18 Jun 2025
28 May 2025
18 Jun 2025
4 Jun 2025
stage.html
html • 0.06 MB
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
fin_eval.pdf
aoc.pdf
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.04 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .